Announced Tue, 14 Oct · 17:42 IST

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.2%1-day move
₹21.99
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+10.2+15.7+21.5+23.0+29.1+34.2+30.2+36.4+26.7+20.7
Up moveDown movePending
AI summary

Venmax Drugs and Pharmaceuticals has submitted a compliance certificate to BSE under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by CIL Securities Limited (the company's Registrar and Share Transfer Agent), confirms that securities received from depository participants for dematerialisation during the quarter ended September 30, 2025 were duly processed, listed on the stock exchange, mutilated and cancelled after verification, and that the depository's name was substituted as registered owner within the stipulated time. The certificate was signed by the Company Secretary on October 14, 2025. No specific financial numbers or share counts are mentioned in the filing.

Likely market impact

This is a routine quarterly compliance filing with no material impact on the company's financials or stock price. It simply confirms that the RTA has properly handled share dematerialisation requests during the quarter, which is a standard regulatory requirement for all listed companies.